<DOC>
	<DOCNO>NCT00040690</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient Burkitt 's lymphoma Burkitt 's leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Burkitt 's Lymphoma Burkitt 's Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Describe morphology , phenotype , cytogenetics , use fresh tumor tissue ( possible ) , patient Burkitt 's Burkitt-like lymphoma/leukemia treat CODOX-M chemotherapy regimen ( cyclophosphamide , vincristine , doxorubicin , methotrexate ) alone alternate IVAC chemotherapy regimen ( ifosfamide , etoposide , cytarabine ) . - Determine whether cytogenetic molecular change associate predictable immunophenotype tumor cell patient characteristic ( e.g. , age ) . - Examine relationship ( 14 ; 18 ) bcl-2 expression patient treat regimen . - Determine whether presence specific cytogenetic molecular change , particular presence ( 14 ; 18 ) ( 8 ; 14 ) , associated adverse outcome ( progression-free overall survival ) patient treat regimen . - Assess activity alternate CODOX-M/IVAC chemotherapy regimen use low dose methotrexate ( compare UKLG LY06 trial ) patient . - Assess activity regimens patient leukemic Burkitt 's lymphoma . - Modify chemotherapy dose regimen include old patient often exclude clinical trial . OUTLINE : This multicenter study . Patients low-risk disease assign group A , patient high-risk disease assign group B . Group A ( low-risk group ) : - Patients receive 3 course CODOX-M chemotherapy regimen comprise cyclophosphamide IV day 1-5 , vincristine IV day 1 8 , doxorubicin IV day 1 , methotrexate ( MTX ) IV 24 hour day 10 . Patients age 65 receive reduced-dose MTX day 10 . All patient receive leucovorin calcium ( CF ) IV hour 36 initiation MTX infusion , every 3 hour hour 36-48 , continue every 6 hour blood level MTX safe . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 13 continue blood count recover . - During 3 course CODOX-M regimen , patient receive CNS prophylaxis comprise cytarabine ( ARA-C ) intrathecally ( IT ) day 1 3 , MTX IT day 15 , oral CF ( 24 hour IT MTX ) day 16 . Group B ( high-risk group ) : - Patients receive CODOX-M chemotherapy regimen ( ) alternate IVAC chemotherapy regimen ( define ) total 4 course give follow sequence : CODOX-M , IVAC , CODOX-M , IVAC . The IVAC chemotherapy regimen comprise ifosfamide ( IFF ) IV 1 hour etoposide IV 1 hour day 1-5 ARA-C IV 3 hour day 1 2 . Patients age 65 receive reduced-dose IFF ARA-C . Patients also receive G-CSF SC daily begin day 7 continue blood count recover . - During IVAC , patient without CNS disease receive MTX IT day 5 oral CF ( 24 hour MTX ) . Patients proven CNS disease receive intensify IT therapy throughout first two course CODOX-M/IVAC chemotherapy . For patient group B CNS disease diagnosis , radiotherapy consider presence cerebral mass document CT scan MRI . Patients group A B develop isolate CNS recurrence ( document malignant CSF pleocytosis , cranial nerve palsy , ) time first course study therapy receive CNS treatment ( ) patient proven CNS disease addition whole brain irradiation 3 week . Patients follow monthly 4 month , every 2 month 8 month , every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A minimum 120 patient ( 30 low-risk disease 90 high-risk disease ) accrue study within approximately 3-4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis diffuse Bcell lymphoma nodal extranodal site CD20 CD79 positive 100 % expression Ki67 ( MIB1 ) tumor cell OR Diagnosis bone marrow replacement/leukemia comprise mature Bcell lymphoma sIg CD19 positive CD34 Tdt negative Patients lowrisk group must meet least 3 follow criterion : Normal lactate dehydrogenase ( LDH ) level WHO performance status 01 Ann Arbor stage I II No 1 extranodal site ( e.g. , bone marrow , gastrointestinal tract , CNS ) Patients highrisk group must meet least 2 follow criterion : Raised LDH level WHO performance status 24 Ann Arbor stage III IV More 1 extranodal site PATIENT CHARACTERISTICS : Age : 16 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics Renal : Not specify Other : No mental physical status would preclude study No disease prior malignancy would preclude study HIV negative Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy except 1 course preinduction chemotherapy ( e.g. , CHOP [ cyclophosphamide , doxorubicin , vincristine , prednisone ] related regimen ) Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
</DOC>